Your session is about to expire
← Back to Search
V940 Vaccine + Pembrolizumab for Melanoma
Study Summary
This trial studies if a customized cancer vaccine plus a drug can prevent cancer from coming back in high-risk melanoma patients.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the combination of V940 and Pembrolizumab received endorsement from the Food & Drug Administration?
"V940 in conjunction with Pembrolizumab garnered a score of 3 due to its existing clinical data which supports both efficacy and safety."
What is the scope of medical practices currently participating in this clinical trial?
"Currently, 12 different medical centres are participating in this clinical trial. This includes facilities located in Montréal, Quebec City and Santiago as well as other locations across the globe. To reduce any travel burden associated with participation, it is best for patients to select a clinic closest to their residence."
Are there still openings for volunteers to partake in this trial?
"Confirmative. Clinicaltrials.gov reports that this medical project, initially posted on July 19th 2023, is currently recruiting potential patients. A total of 1089 participants need to be recruited at a dozen different sites."
What is the current enrollment for this trial?
"Merck Sharp & Dohme LLC is responsible for the organization and execution of this trial, which requires a total 1089 participants matching its eligibility criteria. The investigation will be conducted in two sites: Centre Hospitalier de l'Université de Montréal-Unité de Recherche Clinique en Oncologie et Hématolo located in Montréal and Centre intégré de cancérologie du CHU de Québec Université L-Hemato-Oncology (Site 1101) situated in Quebec City's M. De Santiago region."
Share this study with friends
Copy Link
Messenger